Contact Us
Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2025
Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2025

By Treatment Type (Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types), By Diagnosis Type (Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types), By End Use (Hospitals, Clinics, Other End Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

• Paroxysmal Nocturnal Hemoglobinuria (PNH) market size has reached to $4.24 billion in 2024

• Expected to grow to $6.71 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%

• Growth Driver: Rising Prevalence Of Blood And Bone Marrow Disorders Fueling The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

• Market Trend: Innovative Therapeutic Advancements Lead The Way In Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

North America was the largest region in 2024.

What Is Covered Under Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

Paroxysmal nocturnal hemoglobinuria (PNH) refers to a rare and acquired hematological disorder characterized by the abnormal breakdown of red blood cells (hemolysis) due to a deficiency of certain proteins on the surface of blood cells. It is a debilitating disorder that leads to premature death and impaired production of blood cells. PNH includes a wide range of symptoms, such as fatigue, shortness of breath, abdominal pain and thrombosis (blood clot formation).

The main types of treatments included in paroxysmal nocturnal hemoglobinuria (PNH) are medications, bone marrow transplantation, blood transfusion, immunosuppressive therapy and others. Medications refer to substances that are specifically designed and formulated to diagnose, treat, prevent, or alleviate medical conditions, diseases, or symptoms in humans and animals. Various types of diagnosis include flow cytometry, high-resolution mass spectrometry and others, which are used by several end users, including hospitals, clinics and others.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Size and growth rate 2025 to 2029: Graph

What Is The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Size 2025 And Growth Rate?

The paroxysmal nocturnal hemoglobinuria (PNH) market size has grown rapidly in recent years. It will grow from $4.24 billion in 2024 to $4.67 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to growing demand for paroxysmal nocturnal hemoglobinuria treatment, rising disposable incomes, government initiatives, rising healthcare expenditure.

What Is The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Growth Forecast?

The paroxysmal nocturnal hemoglobinuria (PNH) market size is expected to see strong growth in the next few years. It will grow to $6.71 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to aging population, growing demand for self-administered treatments, increasing access to healthcare, increasing prevalence of comorbidities, growing demand for personalized medicine. Major trends in the forecast period include digital health technologies, development of new and innovative treatments,adoption of gene therapy, early intervention.

The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of complement inhibitor biologics sourced from the UK and Switzerland, thereby delaying life-saving infusions and elevating hematology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Segmented?

1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types

2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types

3) By End Use: Hospitals, Clinics, Other End Users

Subsegments:

1) By Medications: Eculizumab, Ravulizumab, Complement Inhibitors, Supportive Care Medications

2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation, Autologous Stem Cell transplantation

3) By Blood Transfusion: Red blood Cell Transfusion, Platelet Transfusion, Fresh Frozen Plasma Transfusion

4) By Immunosuppressive Therapy: Corticosteroids, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil

5) By Other Treatment Types: Supportive Therapies, Management Of Complications

What Is Driving The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market? Rising Prevalence Of Blood And Bone Marrow Disorders Fueling The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

The rising number of blood disorders and bone marrow-related disorders is expected to propel the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market going forward. Blood disorders are medical conditions that affect the composition, function and production of blood and its components. Bone marrow-related disorders occur when either insufficient red, white, or platelet production occurs in the bone marrow or when the blood cells that are generated are damaged or defective. PNH is closely related to blood disorders and bone marrow-related disorders due to its impact on blood cell production, immune system function and the bone marrow microenvironment. It is a rare blood disorder that is related to bone marrow failure diseases and occurs when a genetic flaw affects how red blood cells and platelets work. For instance, in August 2022, according to Cancer Australia, an Australia-based government agency in 2022, an estimated 5,202 new cases of leukemia will be diagnosed in Australia, with 3,198 cases among males and 2,004 among females. A person has a 1 in 58 (or 1.7%) chance of being diagnosed with leukemia by age 85. This risk is higher for males, at 1 in 47 (2.1%), compared to females, at 1 in 77 (1.3%). Therefore, the rising number of blood disorders and bone marrow-related disorders is driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) industry.

What Is Driving The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market? Rising Demand For Blood Transfusions Drives The Growth Of The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

The rising demand for blood transfusions is expected to drive the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market. A blood transfusion is a medical procedure involving the transfer of blood or blood products from a donor to a recipient. Blood transfusions can be beneficial for individuals with paroxysmal nocturnal hemoglobinuria (PNH) by providing temporary relief from the symptoms and complications associated with this condition. For instance, in June 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, in high-income nations, which comprise only 16% of the world's population, the proportion of blood donations was remarkably significant, accounting for 40% of the total 118.5 million blood donations made worldwide. Additionally, in December 2022, according to the Government of Canada, a Canada-based intergovernmental organization, the UK witnessed an increase in blood donations, with 1.7 million donations made across the country in 2021. Therefore, the rising demand for blood transfusions drives the growth of the paroxysmal nocturnal hemoglobinuria (PNH) industry.

Who Are The Major Players In The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.

What Are The Key Trends Of The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market? Innovative Therapeutic Advancements Lead The Way In Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) market are focusing on developing new and innovative drugs and therapies, such as injectable C5 inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), to sustain their position in the market. An injectable C5 inhibitor is a monoclonal antibody that blocks the complement component C5, reducing inflammation and tissue damage in autoimmune diseases and conditions like paroxysmal nocturnal hemoglobinuria (PNH). For instance, in February 2024, Chugai Pharmaceutical Co., a Japan-based pharmaceutical company, received priority review approval from China's National Medical Products Administration (NMPA) for treating paroxysmal nocturnal hemoglobinuria (PNH). This marks China as the first country to approve PIASKY, ahead of other major markets, allowing IT to enter National Reimbursement Drug List (NRDL) negotiations within the same year. PNH, classified as a rare disease, affects an estimated 12,740 individuals in China, presenting significant market potential.

Need data on a specific region in this market?

What Are Latest Mergers And Acquisitions In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market? Gilead Sciences Acquires Cymabay Therapeutics to Strengthen Liver Disease Treatment Portfolio

In March 2024, Gilead Sciences, Inc., a US-based biopharmaceutical company that discovers, develops, and sells medicines for life-threatening diseases, acquired Cymabay Therapeutics, Inc. for an $4.3 billion amount. With this acquisition, Gilead Sciences, Inc. aims to enhance its liver disease portfolio by introducing seladelpar, a promising treatment for primary biliary cholangitis that addresses significant unmet medical needs. Cymabay Therapeutics, Inc. is a US-based pharmaceutical company that is developing seladelpar as a potential treatment for paroxysmal nocturnal hemoglobinuria (PNH).

Regional Outlook For The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?

The paroxysmal nocturnal hemoglobinuria (PNH) market consists of revenues earned by entities by providing services such as gene therapy, stem cell transplant and complete blood count test (CBC). The market value includes the value of related goods sold by the service provider or included within the service offering. The paroxysmal nocturnal hemoglobinuria (PNH) market also includes sales of Eculizumab and Ravulizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Industry?

The paroxysmal nocturnal hemoglobinuria (pnh) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria (pnh) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $4.67 billion
Revenue Forecast In 2034 $6.71 billion
Growth Rate CAGR of 9.5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types
2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types
3) By End Use: Hospitals, Clinics, Other End Users Subsegments: 1) By Medications: Eculizumab, Ravulizumab, Complement Inhibitors, Supportive Care Medications
2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation, Autologous Stem Cell transplantation
3) By Blood Transfusion: Red blood Cell Transfusion, Platelet Transfusion, Fresh Frozen Plasma Transfusion
4) By Immunosuppressive Therapy: Corticosteroids, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil
5) By Other Treatment Types: Supportive Therapies, Management Of Complications
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson Pvt Ltd, F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire plc, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd, Akari Therapeutics Plc, RA Pharmaceuticals Inc., C5 Therapeutics Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Characteristics

3. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Trends And Strategies

4. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Growth Analysis And Strategic Analysis Framework

5.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Growth Rate Analysis

5.4. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Total Addressable Market (TAM)

6. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Segmentation

6.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Medications

Bone Marrow Transplantation

Blood Transfusion

Immunosuppressive Therapy

Other Treatment Types

6.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Flow Cytometry

High-Resolution Mass Spectrometry

Other Diagnosis Types

6.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

linics

Other End Users

6.4. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Eculizumab

Ravulizumab

Complement Inhibitors

Supportive Care Medications

6.5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Bone Marrow Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Allogeneic Stem Cell Transplantation

Autologous Stem Cell transplantation

6.6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Red blood Cell Transfusion

Platelet Transfusion

Fresh Frozen Plasma Transfusion

6.7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Immunosuppressive Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Corticosteroids

Azathioprine

Cyclophosphamide

Mycophenolate Mofetil

6.8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Supportive Therapies

Management Of Complications

7. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Regional And Country Analysis

7.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

8.1. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

9.1. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

9.2. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

10.1. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

11.1. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

11.2. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

12.1. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

13.1. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

14.1. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

14.2. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

15.1. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

15.2. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

16.1. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

17.1. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

18.1. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

19.1. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

20.1. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

21.1. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

21.2. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

22.1. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

23.1. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

23.2. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

24.1. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

24.2. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

25.1. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

25.2. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

26.1. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

26.2. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

27.1. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

28.1. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

28.2. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

29.1. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview

29.2. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Landscape And Company Profiles

30.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Landscape

30.2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Pvt Ltd Overview, Products and Services, Strategy and Financial Analysis

30.2.3. F. Hoffmann-La Roche AG. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Other Major And Innovative Companies

31.1. Thermo Fisher Scientific Inc.

31.2. Takeda Pharmaceutical Company Limited

31.3. Amgen Inc.

31.4. GE Healthcare

31.5. Regeneron Pharmaceuticals Inc.

31.6. CSL Behring LLC

31.7. Biogen Inc.

31.8. Vertex Pharmaceuticals Incorporated

31.9. Grifols S.A.

31.10. Genentech Inc.

31.11. Shire plc

31.12. Alnylam Pharmaceuticals Inc.

31.13. Innovent Biologics Inc.

31.14. Bioverativ Inc.

31.15. CinnaGen Co

32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

34. Recent Developments In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

35. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market High Potential Countries, Segments and Strategies

35.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In 2029 - Countries Offering Most New Opportunities

35.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In 2029 - Segments Offering Most New Opportunities

35.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Bone Marrow Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Immunosuppressive Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Pfizer Inc. Financial Performance
  • Table 80: Johnson & Johnson Pvt Ltd Financial Performance
  • Table 81: F. Hoffmann-La Roche AG. Financial Performance
  • Table 82: Novartis AG Financial Performance
  • Table 83: Sanofi S.A. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Bone Marrow Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Immunosuppressive Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Pfizer Inc. Financial Performance
  • Figure 80: Johnson & Johnson Pvt Ltd Financial Performance
  • Figure 81: F. Hoffmann-La Roche AG. Financial Performance
  • Figure 82: Novartis AG Financial Performance
  • Figure 83: Sanofi S.A. Financial Performance

Frequently Asked Questions

Paroxysmal nocturnal hemoglobinuria (PNH) refers to a rare and acquired hematological disorder characterized by the abnormal breakdown of red blood cells (hemolysis) due to a deficiency of certain proteins on the surface of blood cells. It is a debilitating disorder that leads to premature death and impaired production of blood cells. PNH includes a wide range of symptoms, such as fatigue, shortness of breath, abdominal pain and thrombosis (blood clot formation). For further insights on this market, request a sample here

The market major growth driver - Rising Prevalence Of Blood And Bone Marrow Disorders Fueling The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market. For further insights on this market, request a sample here

The paroxysmal nocturnal hemoglobinuria (pnh) market size has grown rapidly in recent years. It will grow from $4.24 billion in 2024 to $4.67 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to growing demand for paroxysmal nocturnal hemoglobinuria treatment, rising disposable incomes, government initiatives, rising healthcare expenditure. The paroxysmal nocturnal hemoglobinuria (pnh) market size is expected to see strong growth in the next few years. It will grow to " $6.71 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to aging population, growing demand for self-administered treatments, increasing access to healthcare, increasing prevalence of comorbidities, growing demand for personalized medicine. Major trends in the forecast period include digital health technologies, development of new and innovative treatments,adoption of gene therapy, early intervention. For further insights on this market, request a sample here

The paroxysmal nocturnal hemoglobinuria (pnh)market covered in this report is segmented –
1) By Treatment Type: Medications; Bone Marrow Transplantation; Blood Transfusion; Immunosuppressive Therapy; Other Treatment Types
2) By Diagnosis Type: Flow Cytometry; High-Resolution Mass Spectrometry; Other Diagnosis Types
3) By End Use: Hospitals; Clinics; Other End Users Subsegments:
1) By Medications: Eculizumab; Ravulizumab; Complement Inhibitors; Supportive Care Medications
2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation; Autologous Stem Cell transplantation
3) By Blood Transfusion: Red blood Cell Transfusion; Platelet Transfusion; Fresh Frozen Plasma Transfusion
4) By Immunosuppressive Therapy: Corticosteroids; Azathioprine; Cyclophosphamide; Mycophenolate Mofetil
5) By Other Treatment Types: Supportive Therapies; Management Of Complications For further insights on this market,
request a sample here

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2024. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. For further insights on this market, request a sample here.

Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.. For further insights on this market, request a sample here.

Major trends in this market include Innovative Therapeutic Advancements Lead The Way In Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Back to top WhatsApp icon